|
KMID : 0545120200300121843
|
|
Journal of Microbiology and Biotechnology
2020 Volume.30 No. 12 p.1843 ~ p.1853
|
|
|
Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
|
|
Ku Keun-Bon
Shin Hye-Jin
Kim Hae-Soo
Kim Bum-Tae
Kim Seong-Jun
Kim Chon-Saeng
|
|
|
Abstract
|
|
|
|
COVID-19, caused by the novel coronavirus SARS-CoV-2, has spread globally and caused serious social and economic problems. The WHO has declared this outbreak a pandemic. Currently, there are no approved vaccines or antiviral drugs that prevent SARS-CoV-2 infection. Drugs already approved for clinical use would be ideal candidates for rapid development as COVID-19 treatments. In this work, we screened 1,473 FDA-approved drugs to identify inhibitors of SARS-CoV-2 infection using cell-based assays. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs among those tested showed antiviral activity against SARS-CoV-2. We report this new list of inhibitors to quickly provide basic information for consideration in developing potential therapies.
|
|
|
KEYWORD
|
|
|
SARS-CoV-2, COVID-19, FDA-approved drugs, repurposing screens
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|